Polyphor and the University of Zurich receive an award from Innosuisse to accelerate the development of a new class of antibiotics inhibiting the LPS transport pathway
Polyphor AG / Key word(s): Miscellaneous
Allschwil, Switzerland, May 29, 2019
The project funded by Innosuisse is based on a novel discovery of Prof. John Robinson and Prof. Oliver Zerbe from the UZH concerning the molecular target and mode-of-action of the natural antimicrobial peptide thanatin. Thanatin inhibits the lipopolysaccharide transport protein A (LptA), which is critically involved in the transport of LPS from the periplasm to the outer membrane and of vital relevance to the bacteria.
"This collaboration is a unique opportunity for the UZH and Polyphor to jointly develop antibiotics against priority 1 Gram-negative bacteria to treat infections with high unmet medical need," said Oliver Zerbe, Chief Investigator of the project.
"We are delighted to have obtained the support from Innosuisse, which is a further proof of the potential of our technology platform. This project will allow us to continue a highly fruitful collaboration with the UZH which started in 2000 with a first grant from Innosuisse to develop the protein epitope mimetics (PEM) technology, from which all of Polyphor's current drug portfolio has been developed. Thanatin analogues may lead to another family of compounds inhibiting the outer membrane assembly through a different mechanism than other OMPTAs developed so far," said Daniel Obrecht, Chief Scientific Officer and co-Founder of Polyphor.
Polyphor has discovered, leveraging its macrocycle platform, a new class of antibiotics against Gram-negative bacteria with a novel mode of action, the Outer Membrane Protein Targeting Antibiotics (OMPTA). The most advanced drug candidate of this new class is murepavadin (POL7080), a highly potent antibiotic in clinical development targeting Pseudomonas Aeruginosa, including its most resistant strains, followed by the next generation OMPTAs (lead candidate: POL7306), now in advanced pre-clinical testing, which are medium-spectrum antibiotics targeting the most important Gram-negative pathogens, including extensively drug-resistant and multidrug-resistant strains.
Document title: Polyphor_Innosuisse_29.5.2019
End of ad hoc announcement
|Phone:||+41 61 567 1600|
|Fax:||+41 61 567 1601|
|Listed:||SIX Swiss Exchange|
|EQS News ID:||816921|
|End of Announcement||EQS Group News Service|